NCT07547956 Subcision With Injection of Poly Deoxyribonucleotide Versus Subcision With Injection of Non-cross Linked Hyaluronic Acid in Rolling Acne Scars Treatment.
| NCT ID | NCT07547956 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Atrophic Acne Scars |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-10-20 |
| Primary Completion | 2026-06-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-10-20 with a primary completion date of 2026-06-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate and compare the efficacy and safety of two different injectable agents combined with subcision for treating rolling acne scars. In this split-face clinical trial, each participant will receive subcision on both sides of the face. One side will then be treated with an injection of Polydeoxyribonucleotide (PDRN), while the other side will receive an injection of non-cross linked Hyaluronic acid (HA). The clinical outcomes and improvement in scar appearance will be assessed and compared between both treatments
Eligibility Criteria
Inclusion Criteria: 1. Moderate to severe mainly rolling acne scars per validated scale (Goodman \& Baron Grade 3-4) 2. Scars must be bilaterally distributed, allowing for split-face comparison 3. Stable acne (no active nodulocystic lesions, pustules, or recent outbreaks for ≥6 months) 4. No scar treatments (e.g., fillers, laser, microneedling) within the past 12 months 5. All skin types. 6. Both genders above 18 years old Exclusion Criteria: 1. Systemic retinoid treatment within the last 6 months 2. Active inflammatory acne 3. Lidocaine sensitivity 4. Pregnancy and lactation 5. Severe systemic illness or malignancy 6. Use of anticoagulant or antiplatelet medications (unless cleared) Use of oral isotretinoin within the past 6 month 7. Herpes libialis, bacterial infection, other infections such as HBV, HCV or HIV 8. Tendency to keloid formation 9. Allergy to fish and salmon
Frequently Asked Questions
Who can join the NCT07547956 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrophic Acne Scars. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07547956 currently recruiting?
Yes, NCT07547956 is actively recruiting participants. Visit ClinicalTrials.gov or contact Cairo University to inquire about joining.
Where is the NCT07547956 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07547956 clinical trial?
NCT07547956 is sponsored by Cairo University. The trial plans to enroll 20 participants.